Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044087 | 0.90 | PTPN1 (0.41) | TACR2ALDH1A1RXRARXRBRXRG | |
| SCHEMBL5050784 | 0.87 | MAOA (0.49) | L3MBTL1RAB9ATACR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5047166 | 0.86 | MAOB (0.48) | L3MBTL1RAB9ATACR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL8888740 | 0.76 | APP (0.39) | L3MBTL1NR4A2RAB9ANR4A1NR4A3 | |
| SCHEMBL1406577 | 0.76 | RXRA (0.36) | RXRARXRBRXRG | |
| SCHEMBL5044048 | 0.75 | NR4A2 (0.35) | L3MBTL1NR4A2RAB9ANR4A1NR4A3 | |
| SCHEMBL3068905 | 0.74 | FDPS (0.42) | ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9 | |
| SCHEMBL6917258 | 0.73 | RXRA (0.46) | L3MBTL1NR4A2RAB9ANR4A1NR4A3 | |
| SCHEMBL3062968 | 0.72 | FDPS (0.38) | L3MBTL1ALDH1A1RXRARXRBRXRG | |
| SCHEMBL4946268 | 0.71 | RXRA (0.47) | L3MBTL1NR4A2RAB9ANR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
| EP-1513803-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101945-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | L3MBTL1 4756/4885NR4A2 33/4885RAB9A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.